Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 13;13:840173. doi: 10.3389/fimmu.2022.840173

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 de Almeida, Berzoti-Coelho, Toro, Cacemiro, Bassan, Barretto, Garibaldi, Palma, de Figueiredo-Pontes, Sorgi, Faciolli, Gardinassi and de Castro

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Metabolites differentially abundant in CML patients in comparison with the control group. (A–C) Volcano plots to compare down- and upregulated metabolites in (A). CML patients in the chronic phase (CP; n = 10) and control group (CT; n = 9); (B) CML patients in the advanced phase (AP, n = 13) and control group (CT); (C) CML patients in remission post-TKI therapy (RM; n = 6) and control group (CT). (D) Venn diagram of differentially abundant metabolites in each group, after comparison. (E, F) Scatter-plots of the amount of top predicted metabolites in CML patients and the control group. Sphingosine-1-phosphate was less abundant in CML-AP patients than in the control group. N-Acetylneuraminic acid was more abundant in patients in remission than in control subjects and CML-CP and CML-AP patients. (G) The most representative metabolic pathways in CML patients, compared with the control group. The circle size represents the number of differentially abundant metabolites, and the circle color means the degree of significance (p-value magnitude) after comparison among groups. Significant metabolite features were identified by ANOVA with repeated measures, associated with Tukey’s multiple comparisons test (^* p < 0.05; ^** p < 0.01).